A two-receptor peptide aims at the liver, and heads into the trial that counts

Most of the peptides that make headlines aim at the scale. This one is aimed at the liver. In early August, Altimmune began PERFORMA, a Phase 3 trial of a peptide called pemvidutide, in patients with a liver disease that goes by the initials MASH. A trial starting is a small kind of news, easy to overstate. The more interesting thing is what the molecule is built to do, and how to read the mid-stage results it's carrying into the bigger study.

Two receptors, one of them unusual

Pemvidutide is a dual agonist. Half of it is the familiar part: it activates the GLP-1 receptor, the same target behind semaglutide and the rest of the weight-loss class, which quiets appetite and moves the metabolic dials most people have now heard about. The other half is the reason to pay attention. It also activates the glucagon receptor, in a deliberate one-to-one balance with the GLP-1 side.

Glucagon has a reputation as the hormone that raises blood sugar, which is why turning it on inside a metabolic drug sounds backward at first. But glucagon also acts directly on the liver, pushing it to burn fat rather than store it. That direct-to-liver action is the whole thesis. GLP-1 handles the body-wide metabolic work; glucagon goes at the fat sitting in the organ itself. The design challenge is balance, since the same glucagon signal that clears liver fat can nudge glucose the wrong way if it isn't tuned carefully.

What MASH is, and what the mid-stage trial showed

MASH, metabolic dysfunction-associated steatohepatitis, is the serious end of fatty liver disease: fat, inflammation, and scarring that can progress toward cirrhosis. It's common, it's quiet, and until recently it had almost nothing approved to treat it. That's the unmet need pemvidutide is walking into.

In its Phase 2b trial, called IMPACT, the 24-week numbers were genuinely strong on one measure. MASH resolution without worsening of fibrosis reached about 59 percent and 52 percent at the two doses, against roughly 19 percent on placebo. That is a wide gap, and it earned the drug both Fast Track and Breakthrough Therapy designations from the FDA, which are regulatory signals of promise, not verdicts on outcomes. Later data presented at a European liver meeting extended the picture out to 48 weeks.

The line to read slowly

Here's where a careful reader slows down. "MASH resolution" means the inflammation calmed. Fibrosis, the scarring, is the thing that actually predicts whether a liver fails, and it's harder to move. On the trial's fibrosis-improvement endpoint, the numbers were closer to placebo than the resolution figures were: improvement without worsening landed in the low-to-mid thirties against roughly 26 percent for placebo. A separate, more granular scoring method read more favorably. Two ways of measuring the same scar tissue, two somewhat different stories, which is exactly the kind of detail that gets compressed out of a headline.

None of that makes the result unimpressive. It makes it partial. Calming inflammation over six months is real and useful information. Whether that translates into less scarring, and eventually into livers that hold up over years, is a separate question the mid-stage data can only gesture at.

Why Phase 3 is the test

That gap is what PERFORMA exists to close. It's global, randomized, and placebo-controlled, with a first major readout not expected until 2029. The long timeline isn't bureaucratic drag. Liver scarring changes slowly, and the endpoints that matter, biopsy-confirmed fibrosis regression and hard clinical outcomes, take years and large numbers to establish with any confidence.

So the honest summary is that a two-receptor peptide did something worth noticing in a disease that badly needs options, that its most-quoted number is stronger than its fibrosis number, and that the trial capable of settling the difference has only just begun. A Phase 3 start is the opening of the real experiment, not its answer. The useful posture is patience: interested, not sold, and willing to wait for the part of the story that hasn't been written yet.

---

This post is educational and general in nature. It is not medical advice. For guidance about your own health, talk to a qualified clinician.